Cogent Biosciences, Inc. (COGT) Revenue History
Annual and quarterly revenue from 2015 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2019)
COGT's revenue distribution by segment and geography for fiscal year 2019
By Product/Segment
COGT Revenue Analysis (2015–2025)
As of February 28, 2026, Cogent Biosciences, Inc. (COGT) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q4 2025) recorded $0 in revenue.
Looking at the longer-term picture, COGT's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $22.5 million in 2019.
Revenue diversification analysis shows COGT's business is primarily driven by Preclinical Research And Clinical Development (100%). With over half of revenue concentrated in Preclinical Research And Clinical Development, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including AGIO (+36.3% YoY), VRTX (+10.4% YoY), and ASND (+97.4% YoY). Compare COGT vs AGIO →
Peer Comparison
Compare COGT's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| COGTCurrent | $0 | - | - | - | |
| AGIO | $54M | +36.3% | - | -873.9% | |
| VRTX | $12.0B | +10.4% | +14.1% | 39.1% | |
| ASND | $692M | +97.4% | +150.9% | -18.9% | |
| BBIO | $502M | +126.3% | +127.4% | -113.3% | |
| BMRN | $3.2B | +12.9% | - | 16.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-4,619,000 | - | $-333,363,000 | - |
| 2024 | $0 | - | $0 | - | $-275,939,000 | - |
| 2023 | $0 | - | $0 | - | $-208,130,000 | - |
| 2022 | $0 | - | $0 | - | $-147,839,000 | - |
| 2021 | $0 | -100.0% | $0 | - | $-75,551,000 | - |
| 2020 | $7.9M | -65.0% | $-17,867,000 | -227.0% | $-82,199,000 | -1044.3% |
| 2019 | $22.5M | +131.1% | $22.5M | 99.8% | $-32,178,000 | -143.0% |
| 2018 | $9.7M | +16.4% | $9.7M | 100.0% | $-36,005,000 | -369.9% |
| 2017 | $8.4M | +31.6% | $8.4M | 100.0% | $-26,152,000 | -312.8% |
| 2016 | $6.4M | +112.8% | $6.4M | 100.0% | $-19,070,000 | -300.1% |
See COGT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs COGT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare COGT vs AGIO
See how COGT stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is COGT's revenue growth accelerating or slowing?
COGT TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is COGT's long-term revenue growth rate?
Cogent Biosciences, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is COGT's revenue distributed by segment?
COGT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2015-2025 are available for download. Segment mix reveals concentration and diversification trends.